Hung Trinh, Senior VP of Operations at Seneca Therapeutics, shared a post on LinkedIn:
“Review: Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity.
Plasticity is a hallmark of aggressive tumors, including glioblastoma (GBM), enabling tumor cells and the tumor microenvironment (TME) to adapt to diverse niches and evade treatment.
Here, we discuss how innate and adaptive immune players cooperate in time and space to create an immunosuppressive TME that supports GBM growth and confers resistance to conventional treatments and immunotherapies. We highlight how therapeutic interventions reshape the TME, underscoring the need for targeted approaches to overcome resistance.
We introduce the concepts of local TME priming and TME rewiring as necessary foundations for achieving more effective and durable clinical responses in the future. Remodeling of the GBM immune microenvironment upon SoC.
In the following sections, we examine the literature focused on how treatments reshape the GBM immune landscape and the implications for the design of therapeutic interventions.
The current SoC involves surgical resection followed by radiotherapy with concomitant and adjuvant TMZ, while anti-VEGF therapy (bevacizumab) is primarily applied in the recurrent scenario2.
Standard therapies exert considerable systemic and local immune effects, but they fail to achieve durable immune activation. Here, we discuss the direct and indirect effects of treatment on systemic and local immunity”
Other articles about Glioblastoma on OncoDaily.